183 related articles for article (PubMed ID: 9448028)
1. Infectious vaccines.
Ross DW
Arch Pathol Lab Med; 1998 Jan; 122(1):100-1. PubMed ID: 9448028
[No Abstract] [Full Text] [Related]
2. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
3. The first identified hepatitis B virus vaccine escape mutation in Turkey.
Kutlu T; Soycan LY; Karatayli E; Türkyilmaz AR; Yurdaydin C; Bozdayi AM
J Clin Virol; 2006 Feb; 35(2):201-2. PubMed ID: 16230046
[No Abstract] [Full Text] [Related]
4. Virology. 'Biased' viruses suggest new vaccine strategy for polio and other diseases.
Enserink M
Science; 2008 Jun; 320(5884):1709. PubMed ID: 18583587
[No Abstract] [Full Text] [Related]
5. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
Whelan SP; Evans D; Almond JW
Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
[No Abstract] [Full Text] [Related]
7. Salk group testing killed-virus AIDS vaccine.
Minn Med; 1994 Jul; 77(7):55. PubMed ID: 8052210
[No Abstract] [Full Text] [Related]
8. Live attenuated AIDS vaccines: hazards and hopes.
Johnson RP
Nat Med; 1999 Feb; 5(2):154-5. PubMed ID: 9930861
[No Abstract] [Full Text] [Related]
9. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
[TBL] [Abstract][Full Text] [Related]
10. [Advantages and disadvantages of antipoliomyelitis vaccines prepared with live and killed viruses].
Melnick JL
Bol Oficina Sanit Panam; 1980 Jun; 88(6):507-29. PubMed ID: 6448065
[No Abstract] [Full Text] [Related]
11. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
[TBL] [Abstract][Full Text] [Related]
12. Tepid endorsement for HIV vaccine trial.
Science; 1995 Feb; 267(5200):966. PubMed ID: 7863340
[No Abstract] [Full Text] [Related]
13. DNA vaccines against human immunodeficiency virus type 1.
Estcourt MJ; McMichael AJ; Hanke T
Immunol Rev; 2004 Jun; 199():144-55. PubMed ID: 15233732
[TBL] [Abstract][Full Text] [Related]
14. The roads travelled.
Billard L
Biometrics; 1995 Mar; 51(1):1-11. PubMed ID: 7766766
[No Abstract] [Full Text] [Related]
15. India targets local HIV strain in test of AIDS vaccine.
Jayaraman KS
Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601
[No Abstract] [Full Text] [Related]
16. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
18. Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS).
National Advisory Committee on Immunization (NACI)
Can Commun Dis Rep; 2007 Feb; 33(ACS-1):1-14. PubMed ID: 17294559
[No Abstract] [Full Text] [Related]
19. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland.
Martín J; Ferguson GL; Wood DJ; Minor PD
Virology; 2000 Dec; 278(1):42-9. PubMed ID: 11112479
[TBL] [Abstract][Full Text] [Related]
20. The prospective preventative HIV vaccine based on modified poliovirus.
Zhang YD; Lu XL; Li NF
Med Hypotheses; 2007; 68(6):1258-61. PubMed ID: 17196342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
